NDAORALTABLET
Approved
Jul 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ZESTORETIC (lisinopril and hydrochlorothiazide) by Almatica Pharma is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, to lower blood pressure. First approved in 1989.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZESTORETIC is a fixed-dose oral combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) approved in 1989 for hypertension management. Lisinopril blocks angiotensin II formation to reduce vasopressor activity and aldosterone secretion, while hydrochlorothiazide increases sodium and chloride excretion to lower blood volume. The combination addresses both renin-angiotensin system dysfunction and fluid overload, providing synergistic blood pressure reduction.
$0.883MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with modest Part D spending ($883K) and declining utilization, signaling a mature brand team focused on retention and generic transition planning.
Mechanism of Action
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Pharmacologic Class:
Thiazide Diuretic
Indications (2)
Worked on ZESTORETIC at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.